The management of coronavirus infections with particular reference to SARS
暂无分享,去创建一个
[1] D. Tyrrell,et al. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers , 1983, Antimicrobial Agents and Chemotherapy.
[2] Y. Guan,et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.
[3] J. Dennis,et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.
[4] P. Woo,et al. Viral Loads in Clinical Specimens and SARS Manifestations , 2004, Emerging infectious diseases.
[5] Y. Guan,et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds , 2004, Journal of Clinical Virology.
[6] Tsung-Han Hsieh,et al. Severe acute respiratory syndrome coronavirus 3C‐like protease‐induced apoptosis , 2006, FEMS immunology and medical microbiology.
[7] B. Berkhout,et al. Antiviral strategies against human coronaviruses. , 2007, Infectious disorders drug targets.
[8] Marc Van Ranst,et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine , 2004, Biochemical and Biophysical Research Communications.
[9] C. Castilletti,et al. Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus , 2006, Antiviral therapy.
[10] Jindrich Cinatl,et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.
[11] Lirong Chen,et al. Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells , 2004, Journal of Virology.
[12] Paul Garner,et al. SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.
[13] H. Vennema,et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization , 1990, Journal of virology.
[14] W. Lim,et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome , 2004, The Lancet.
[15] E. De Clercq,et al. Potential antivirals and antiviral strategies against SARS coronavirus infections , 2006, Expert review of anti-infective therapy.
[16] Xin Li,et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. , 2003, The New England journal of medicine.
[17] V. Wong,et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.
[18] B. Berkhout,et al. Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle , 2006, Antimicrobial Agents and Chemotherapy.
[19] J. Sung,et al. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.
[20] Yan Liu,et al. Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine , 2007, Antiviral therapy.
[21] P. Chan,et al. Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[22] T. Rochat,et al. A Prospective Hospital-Based Study of the Clinical Impact of Non–Severe Acute Respiratory Syndrome (Non-SARS)–Related Human Coronavirus Infection , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Elizabeth Rea,et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.
[24] V. Wong,et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak , 2004, Thorax.
[25] Jindrich Cinatl,et al. Development of antiviral therapy for severe acute respiratory syndrome , 2005, Antiviral Research.
[26] P. Chan,et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital , 2005, The Journal of antimicrobial chemotherapy.
[27] Stefan Ma,et al. Secondary Household Transmission of SARS, Singapore , 2004, Emerging infectious diseases.
[28] L. Chiang,et al. ANTIVIRAL EFFECTS OF SAIKOSAPONINS ON HUMAN CORONAVIRUS 229E IN VITRO , 2006, Clinical and experimental pharmacology & physiology.
[29] Jindrich Cinatl,et al. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines , 2004, Biochemical and Biophysical Research Communications.
[30] W. Lam,et al. Management of severe acute respiratory syndrome: the Hong Kong University experience. , 2003, American journal of respiratory and critical care medicine.
[31] B. Haagmans,et al. Coronaviruses and their therapy , 2006, Antiviral Research.
[32] C. Meschievitz,et al. Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon , 1986, The Journal of infectious diseases.
[33] G. Bren,et al. Flying in the Face of Resistance: Antiviral‐independent Benefit of HIV Protease Inhibitors on T‐cell Survival , 2007, Clinical pharmacology and therapeutics.
[34] S. Bondy,et al. Household transmission of SARS, 2003 , 2006, Canadian Medical Association Journal.
[35] Tze Wai Wong,et al. Probable Secondary Infections in Households of SARS Patients in Hong Kong , 2004, Emerging infectious diseases.
[36] J. Lepault,et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[37] Yi Guan,et al. Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.
[38] H. Hsieh,et al. Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide , 2004, Antimicrobial Agents and Chemotherapy.
[39] Jongdae Lee,et al. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin , 2006, Antiviral Research.
[40] L. Poon,et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .
[41] V. Cheng,et al. Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection , 2007, Clinical Microbiology Reviews.
[42] Elizabeth J Phillips,et al. Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] V. Wong,et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. , 2003, Hong Kong medical journal = Xianggang yi xue za zhi.
[44] Y. Guan,et al. Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.
[45] Cheng Luo,et al. Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features , 2006, Bioorganic & Medicinal Chemistry.
[46] A. Ahuja,et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy , 2006, Pathology.